Spontaneous coronary artery dissection: an unpredictable event

Abstract

Spontaneous coronary artery dissection (SCAD) is an under-recognized cause of acute coronary syndrome that predominantly affects women in adulthood and is the leading cause of acute myocardial infarction in pregnancy. The most common clinical presentation is ST-segment elevation myocardial infarction (STEMI) or non-STEMI, followed by cardiogenic shock (∼2%), sudden cardiac death (0.8% in autopsy series), cardiac arrest, ventricular arrhythmias (∼5%), and Takotsubo syndrome. The prevalence of SCAD in the general population is largely uncertain due to underdiagnosis. Oral contraceptives, post-menopausal therapy, and infertility treatments are recognized associated factors. The pathological substrates (fibromuscular dysplasia) and triggers (especially emotional stress) are commonly present in affected women. The few cases with a precise genetic aetiology occur in the context of syndromic and non-syndromic connective tissue diseases. The only true certainty in SCAD is the overwhelming prevalence in women. The first event as well as the recurrence (up to 30%, which varies depending on the definition) is largely unpredictable. The treatment strategy is highly individualized and requires extensive additional study in order to optimize outcomes and prevent major adverse cardiovascular events in affected individuals. We have known about SCAD for nearly a century, but we still do not know how best to prevent, diagnose, and treat it, making SCAD a highly important and unmet clinical need.

Introduction

Spontaneous coronary artery dissection (SCAD) is defined as an ‘epicardial coronary artery dissection that is not associated with atherosclerosis or trauma and is not iatrogenic’.¹ Spontaneous coronary artery dissection is an important yet under-recognized cause of acute coronary syndrome (ACS) and constitutes up to 4% of all ACS cases.¹ It occurs predominantly in middle-aged women without conventional risk factors for atherosclerotic coronary artery disease. Spontaneous coronary artery dissection is the cause of acute myocardial infarction (AMI) in 22–43% of women ≤50 years of age² and is the most common cause of pregnancy-associated AMI (43%).³ There are limited data, however, that have shed light on the precise aetiology, genetic basis, and predictors of SCAD recurrence. This review summarizes the definition and classification of SCAD, known associated factors and triggers, underlying diseases, potential toxic contributors (e.g. drugs), diagnosis and treatment, and recurrence rate and risk, in addition to what we delineate as familial vs. non-familial and syndromic vs. non-syndromic SCAD.

Clinical issues

Clinical presentation

The most common recognized clinical manifestation of SCAD is AMI in the context of ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI).¹ Less typical manifestations at onset include cardiogenic shock (∼2%),⁴ sudden cardiac death (SCD)⁵ (0.8% in autopsy series of SCD),⁶ cardiac arrest,^1,7 ventricular arrhythmias (∼5%),¹ and Takotsubo syndrome. The most common symptoms include chest pain with potential radiation to the left arm or neck, nausea/vomiting, dyspnoea, and diaphoresis. Early symptoms are often ignored, and there is a latency period between symptom onset and medical attention. Symptoms post-SCAD are similarly common, and often include chest pain even in the absence of a recurrent event. Troponin levels are generally increased, but can be normal.⁸

Diagnosis and classification

Spontaneous coronary artery dissection should be considered in women with a paucity of atherosclerotic risk factors and who present with ACS. This clinical suspicion warrants immediate assessment with urgent coronary angiography.¹ Spontaneous coronary artery dissection is classified into three distinct angiographic types. Type 1 SCAD is characterized by contrast entering the false lumen, which is seen in less than one-third of patients. Type 2 SCAD is the most common, seen in up to two-thirds of patients, and has the appearance of a long, smooth, and diffusely narrowed segment with an intra-mural haematoma. This type carries the highest risk of being undetected on angiography. Type 3 SCAD is the least common and can mimic atherosclerotic lesions given its focal appearance.⁹ The diagnostic confirmation of Types 2 and 3 SCAD may require intra-coronary imaging including optical coherence tomography and intra-vascular ultrasound (IVUS).¹⁰ Cardiac coronary tomography angiography is not recommended to be a first-line imaging modality of SCAD because small and non-proximal dissections can be missed.^1,10

Treatment

Appropriate management of SCAD relies on precision diagnosis and aims at controlling symptoms, improving outcomes, and preventing recurrence. However, the treatment of SCAD is highly individualized.¹¹ Spontaneous healing seems to occur weeks to months after the acute episode in most cases. In a large multi-centre series, most SCAD patients were treated conservatively (84.3%), 14.1% of patients underwent percutaneous coronary intervention (PCI), and 0.7% of patients had coronary artery bypass surgery (CABG).¹² There are no guidelines for treating SCAD-related ACS, and current treatment strategies are based on expert opinion.¹³ The general trend of first-line treatment is medical therapy alone.^1,4,13 Antiplatelet therapy and beta-blockers are usually initiated in haemodynamically stable patients. The potential risk of dissection and intra-mural haematoma precludes the safe administration of thrombolytic therapy. Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers are administered in patients with significant LV dysfunction, and statin therapy is recommended only in patients with pre-existing dyslipidaemia or known atherosclerotic disease. Although PCI may be complicated by the risk of iatrogenic catheter–induced dissection and propagation of SCAD, patients with STEMI are more frequently treated with IVUS-guided primary PCI (31 vs. 16%, P < 0.001). Optical coherence tomography should be considered as a second option due to the risk of dissection propagation related to dye infusion during pullback.¹⁴ Finally, CABG is uncommonly performed and considered in patients with left main coronary artery dissection or multi-vessel disease after failed primary PCI.¹

Recurrence

The term ‘recurrence’ can describe the extension of the dissection along the same vessel or a de novo dissection affecting different segments of the same coronary artery (CA) or different CAs. Although the risk of recurrence of SCAD is up to 30%,^1,12 a recent prospective observational study reported recurrence in 2% of cases over a median follow-up of 2 years.¹⁵ A recurrent myocardial infarction in up to 10%, including 2.4% de novo recurrent SCAD, occurred over a median follow-up of 3 years in another recent multi-centre prospective observational study.¹⁶ Coronary artery tortuosity has been reported to be a risk factor for recurrence.¹⁷

Pathogenesis

Spontaneous coronary artery dissection is not attributable to a single identified pathogenic mechanism. There is heterogeneity in terms of triggers, circumstances, and underlying predisposing disorders. The hormonal hypothesis/contribution is of course of pertinence, given the overwhelming prevalence of SCAD in women. Fibromuscular dysplasia (FMD), chronic inflammatory and autoimmune diseases, genetic causes related to monogenic syndromes associated with arterial dissection risk, hypertension, and physical and emotional triggers have been reported.

Female sex hormones

Spontaneous coronary artery dissection can occur in both childbearing and post-menopausal age, in both multiparous (>4 pregnancies) and nulliparous women, in uncomplicated pregnancies (70% in the early post-partum) as well as in complicated pregnancies (eclampsia and pre-eclampsia).^3,18 Administration of exogenous hormones is a potential risk factor, including oral contraception, post-menopausal therapy, and infertility treatments.¹⁹ During pregnancy, hormonal changes, vasomotor tone, increased blood volume, and flow modifications may contribute to transient epicardial coronary artery fragility that may constitute a potential substrate favouring the occurrence of SCAD.^1,3,12 Pregnancies of women carriers of defects in genes associated with known heritable arteriopathies must be monitored and protected even if the arterial disease has not yet clinically manifested. This suggestion also applies to pregnancies of women who are members of families in which a SCAD event has occurred, irrespective of the identification of the genetic causes. Spontaneous coronary artery dissection has to be included in the list of causes of cardiovascular death in pregnancy, and together with peripartum cardiomyopathy, Takotsubo syndrome, arrhythmias, and aortic dissection, they account for up to one-third of all pregnancy-related maternal deaths.²⁰

Fibromuscular dysplasia

Fibromuscular dysplasia is a non-atherosclerotic, non-inflammatory arteriopathy that primarily manifests as beading (multi-focal FMD) or focal lesions in medium- or small-sized arteries, although the clinical phenotype of FMD has recently expanded to include arterial dissection, aneurysm, and tortuosity.²¹ Approximately 80–90% of patients with FMD are women. Up to 86% of screened patients with SCAD have FMD. The diagnosis of FMD is made via imaging in the form of angiography, computed tomographic/magnetic resonance angiography, or duplex ultrasound. In a study addressing the prevalence of FMD among 50 SCAD patients, 12% had >1 dissected coronary artery. A total of 86% of SCAD patients had an FMD of ≥1 non-coronary artery.²² In addition, FMD was recently noted to be an independent predictor of 3-year major adverse cardiovascular events (MACE) in patients with SCAD.¹⁶

Systemic autoimmune and inflammatory diseases

Although chronic inflammatory and autoimmune diseases have been reported in patients with SCAD, the association is not common (4.7%).¹² Specifically, SCAD has been described in case reports of patients with various systemic inflammatory diseases, including systemic lupus erythematosus, rheumatoid arthritis, Crohn’s disease, inflammatory bowel disease, polyarteritis nodosa, sarcoidosis, Churg–Strauss syndrome, Wegener granulomatosis, Kawasaki disease, cryoglobulinemia, hypothyroidism, thyroid storm, and autoimmune thyroiditis.^1,12,23

Autoimmune diseases are more common in female patients, and causation has not yet been established.

Genetic arteriopathies

Clinically, SCAD rarely clusters within families with genetic arteriopathies. A positive family history of SCAD is reported in ∼1% of cases,^1,2,24 and most cases are sporadic. Despite this limited evidence, genetic causes have been extensively investigated and are plausibly associated with the event in a proportion of patients ranging between 5 and 17%. (References are listed as PMID in Figure 1.) This range is due to multiple factors: patient selection; deep clinical phenotyping encompassing not only the SCAD event but the arterial vascular tree as a whole; and the genetic testing strategy, from single gene to multigene panels, up to whole-exome sequencing. Although research specifically dedicated to the identification of one or more SCAD-specific genes has been carried out, no gene is currently validated whose defects are selectively associated with SCAD. Gene defects tend to occur in syndromic contexts associated with hereditary–familial arterial disease. Among these, COL3A1, whose defects cause vascular Ehlers–Danlos syndrome (EDS IV), is the most common disease gene. Pathogenic variants in COL3A1 are reported from at least nine reputable scientific sources. In an extensive review including data from 737 patients with genetically confirmed EDS IV, 26 patients had SCAD either at the onset or during the course of the disease.²⁵COL3A1 is followed by FBN1, whose genetic defects cause Marfan syndrome, by the genes whose defects cause Loeys–Dietz syndromes 1–6 (TGFBR1, TGFBR2, TGFB3, TGFB2, SMAD3, and SMAD2), and finally by other rare genes associated with syndromic and non-syndromic thoracic aortic aneurism/thoracic acute aortic dissection, including extremely rare diseases such as pseudoxanthoma elasticum.²⁶ Genetic disorders were discovered to be an independent predictor of 3-year MACE in patients with SCAD.¹⁶ The identification of the genetic causes of SCAD also impacts the risk of dissection at extracoronary sites. It sheds light on clinically relevant disease manifestations (e.g. risk of bowel or uterine rupture in EDS IV), which warrant select/serial monitoring. Furthermore, the detection of pathogenic variants in the proband facilitates family screening, which allows for the identification of affected asymptomatic family members as well as young healthy carriers of the putative genetic defect.

Hypertension

Hypertension is common in SCAD survivors (45% of cases). It is one of the traditional risk factors identified post-SCAD along with hypercholesterolaemia. Patients with SCAD and hypertension are older, more often post-menopausal, and have more extensive coronary artery involvement than SCAD patients with normal blood pressure.^27,28 Hypertensive SCAD patients undergoing revascularization exhibit an increased risk of procedural-related complications.

Stressors and triggers

Intense physical or emotional stress is a potential contributor or trigger of SCAD. A large multi-centre study reported emotional stress in 50.3% and physical stress in 28.9% (9.8% lifting >50 pounds),¹¹ confirming prior values of emotional stress (56.5% of 168) reported in a smaller series by the same authors.¹² In other series, however, the prevalence of emotional stress was lower (26.0%), demonstrating that the qualitative and quantitative evaluation of the stressors can be variable. In any case, traditional female-associated risk factors for SCAD, such as depression, anxiety, emotional stress, and migraines, are more common in women than in men. Illicit drug use, in particular cocaine and amphetamine abuse, can further contribute. Finally, the co-occurrence of SCAD and stress cardiomyopathy, although anecdotally reported, suggests the possibility that intense stressors, more frequent in women, may be similar in the two conditions.^29,30

Considerations

Although some risk factors and triggers are known, SCAD is an acute coronary event that cannot be predicted yet. Known ‘predisposing’ conditions are not sufficient to identify women at risk for a first event and for recurrence. Even in the presence of precise causes such as pathogenic defects in genes associated with heritable arterial diseases, definite protection of the coronary tree is challenging since there is no evidence that SCAD is preceded by aneurysmal dilatation of the coronary arteries as can occur at other arterial sites.

Future efforts should focus on the precise diagnosis of SCAD, especially Types 2 and 3 (standard intra-coronary imaging implementation?), in all acute non-atherosclerotic coronary syndromes in women, and on the annotation of prodromal symptoms, circumstances, and drugs as well as underlying systemic diseases, with the goal of collecting data more so than drawing absolute conclusions. While we have known about SCAD for almost a century,³¹ we still do not know how best to prevent, diagnose, and treat it, rendering it an important and unmet clinical need.

Funding

Research on coronary artery disease and heritable arteriopathies is supported by continuous RC funds on heritable connective tissue diseases from the Italian Ministry of Health to the Fondazione IRCCS Policlinico San Matteo, n. 221-rcr2000b-8 and n. 888-rcr2017i-71 projects; project RCR-2019-23669116_001 (CV-PREVITAL) from the Italian Ministry of Health; Telethon grant n.GGP08238 for Marfan Syndrome; FRRB grant n.CP2_14/2018 for coronary artery disease and monogenic arteriopathies.

Data availability

No new data were generated or analysed in support of this research.

References

Author notes